TEVA(US:TEVA) Benzinga·2025-11-05 16:30Financial Performance - Teva Pharmaceutical Industries Ltd. reported total revenue of $4.48 billion for Q3 2025, exceeding analysts' expectations of $4.35 billion [1] - Revenues increased by 3% year-over-year in U.S. dollars, or 1% in local currency [1] - Adjusted earnings were reported at 78 cents per share, surpassing the consensus of 66 cents and up from 69 cents a year ago [4] Key Product Performance - Sales of Austedo, a drug for Huntington's disease, rose by 38% to $618 million, with an increased revenue outlook for 2025 of $2.05 billion to $2.15 billion [2] - Ajovy, a migraine treatment, achieved sales of $168 million, reflecting a 19% increase in local currency year-over-year, with a reaffirmed 2025 revenue outlook of $630 million to $640 million [2] - Uzedy, a schizophrenia drug, generated revenues of $43 million, up 24%, with a reaffirmed 2025 revenue outlook of $190 million to $200 million [3] Guidance and Outlook - Teva raised its fiscal year 2025 adjusted earnings guidance from $2.50-$2.60 per share to $2.55-$2.65, compared to the consensus of $2.58 [5] - The company narrowed its 2025 sales guidance from $16.8 billion-$17.2 billion to $16.8 billion-$17 billion, against a consensus of $16.89 billion [5] Market Position and Stock Performance - Teva's stock increased by 18.23% to $24.19 following the earnings report [6] - The CEO indicated that the company is well-positioned for potential U.S. tariffs, with nine manufacturing plants in operation [6]